# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frederick Law Olmsted (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI022-SYN
- Date: 2026-08-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nathan Calder, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month dementia review. **S**

## History of present illness

Mr. Olmsted returns with his caregiver three months after his first visit, nine weeks after starting donepezil 5 mg each morning. He has had no nausea, diarrhea, loss of appetite, dizziness, fainting, or vivid dreams. His caregiver feels he is a little more engaged in the mornings, and his memory is otherwise unchanged. The night-time confusion during his cold three weeks ago stopped as soon as the diphenhydramine cold medicine was stopped, and his cough has gone. He stopped driving after the consultation and walks with company most days. He wears a medical identification bracelet. His caregiver completed the Zarit Burden Interview today and describes broken sleep, worry about leaving him alone, and little time off. **S**

| Element | Detail |
|---|---|
| Medicine | Donepezil 5 mg for nine weeks; no side effects |
| Course | Memory unchanged; slightly more engaged in the mornings |
| Interval illness | Cold with night-time confusion from diphenhydramine three weeks ago, resolved |
| Safety | No driving; medical identification bracelet; no wandering |
| Caregiver | Zarit Burden Interview 24; broken sleep and little time off |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No nausea, diarrhea, or loss of appetite |
| Cardiovascular | Negative | No fainting or lightheadedness |
| Neurological | Positive | Memory loss unchanged; no night-time confusion since the antihistamine was stopped |
| Psychiatric | Negative | Mood steadier; no hallucinations or agitation |

4 systems reviewed. **S**

## Current medications

- Donepezil 10 mg oral tablet, one tablet by mouth each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/76 mmHg; pulse 62 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 71.2 kg; BMI 23.2 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Alert, pleasant, and engaged |
| Cardiovascular | Regular rhythm at 62 per minute; blood pressure 128/76 mmHg; weight 71.2 kg |
| Neurological | Oriented to person and place, not to date; no new focal signs; normal gait |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Mild dementia, type undetermined** (F03.A0). Donepezil 5 mg tolerated; heart rate 62 with no fainting, and weight down 0.6 kg in two months. No new behavioral symptoms. Caregiver burden is moderate (Zarit 24, above the threshold of 21). **S**
   - Increase donepezil to 10 mg each morning; report fainting, slow pulse, vomiting, diarrhea, or weight loss.
   - Caregiver: education program and a trial of an adult day program two days a week; Alzheimer's Association respite information.
   - Advance care planning completed today.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Medication review with the AGS Beers Criteria (anticholinergic burden, sedatives, sleeping pills, antipsychotics) | Every visit | Completed today | Diphenhydramine cold medicine stopped after the sick visit; no anticholinergic or sedating drugs now |
| Survey | Neuropsychiatric symptom screen (NPI-Q) | Every visit | Completed today | Mild apathy, less in the mornings; no hallucinations, agitation, or wandering; the night-time confusion has not recurred |
| Medication safety | Cholinesterase inhibitor tolerability and benefit: heart rate, fainting, nausea, diarrhea, weight, sleep and dreams | Each follow-up on treatment | Completed today | On 5 mg for nine weeks: heart rate 62, no fainting, no gastrointestinal effects, weight 71.2 kg (down 0.6 kg), no vivid dreams; increasing to 10 mg |
| Medication safety | Antipsychotic appropriateness and taper review | Every visit if on an antipsychotic | Not indicated | Not on an antipsychotic |
| Examination | Vascular risk-factor control (blood pressure, lipids, glucose, smoking) | Every visit | Completed today | Blood pressure 128/76 mmHg; lipids at the wellness visit |
| Examination | Home safety evaluation | At diagnosis and each follow-up | Deferred | The home safety checklist given at diagnosis was not reviewed at this visit, a deviation from the each-follow-up item. There have been no falls, burns, or wandering, so no harm is evident. Corrective action: the checklist is reviewed at the six-month visit |
| Survey | Cognitive test (MoCA) | Annually; every visit if a change is reported | Up to date | MoCA 19 three months ago; no change reported |
| Survey | ADL (Katz) and IADL (Lawton-Brody) | Annually, and at any reported change | Up to date | No change reported since the first visit |
| Survey | Dementia stage (CDR or FAST) | Annually | Up to date | CDR 1 two months ago |
| Survey | Depression screen (PHQ-9) | Annually, and at any reported change | Up to date | PHQ-9 6 three months ago; mood steadier today |
| Examination | Fall-risk assessment (Timed Up and Go, gait and balance) | Annually | Up to date | No falls; Timed Up and Go 11 seconds three months ago |
| Examination | Driving safety (CDR-based) | At diagnosis and annually | Completed today | No driving since the consultation |
| Self-management | Firearms, wandering, and financial safety | At diagnosis and with any change | Completed today | No firearms; medical identification bracelet worn; no wandering; caregiver oversees finances |
| Survey | Caregiver burden (Zarit Burden Interview) and caregiver needs | At diagnosis, then every 6 to 12 months | Completed today | Zarit Burden Interview 24, moderate burden (21 or more): education, adult day program, and respite information given; the item missed at diagnosis is now done |
| Self-management | Advance care planning and goals of care | At diagnosis, then annually and at stage changes | Completed today | Health care agent named and his values and wishes recorded today, with him taking full part |
| Laboratory | TSH, vitamin B12, blood count, and metabolic panel | At diagnosis; repeat only with acute cognitive worsening | Up to date | Normal at diagnosis; no acute change to repeat them |
| Laboratory | Syphilis and HIV testing | Only with risk factors or atypical features | Not indicated | No risk factors |
| Imaging | Structural brain MRI, non-contrast | Once at diagnosis; repeat only with an atypical course or focal change | Up to date | Done once at diagnosis; no atypical course |
| Laboratory | Amyloid or tau biomarkers (blood, CSF, or amyloid PET) and APOE genotype | Before anti-amyloid therapy, or when the result would change care | Not indicated | Declined two months ago; no change in his wishes |
| Imaging | Anti-amyloid antibody therapy with ARIA surveillance MRI | Only if anti-amyloid therapy is started | Not indicated | Not chosen |
| Self-management | Lifestyle: aerobic exercise about twice a week, hearing, vision, sleep, social engagement | Ongoing | Completed today | Walks most days with company; adult day program will add social contact |
| Referral | Dementia care navigation and caregiver support program | At enrollment, with ongoing support | Completed today | Caregiver education program and adult day program arranged |
| Self-management | Vaccination status (influenza, pneumococcal, zoster, COVID-19, Tdap) | Yearly, per the CDC schedule | Due | At the wellness visit in about six weeks |

## Goal progress

- Complete the reversible-cause tests and brain MRI and discuss the diagnosis with him and his caregiver by the four-week visit. Outcome by 2026-06-02: Tests and MRI showed no reversible cause; diagnosis of mild dementia of undetermined type discussed with both. **S**
- A safety plan in place by the three-month review: no driving, medicines supervised, finances overseen, and medical identification worn. Outcome by 2026-08-04: Stopped driving after the consultation; caregiver gives medicines from a weekly organizer and oversees bill paying with his agreement; medical identification bracelet worn. **S**
- Donepezil at 10 mg daily without side effects and with resting heart rate 55 or above by the six-month review. In progress; target 2026-10-27. **S**
- Caregiver burden assessed and support in place by the six-month review. In progress; target 2026-10-27. **S**
- Name a health care agent and record his values and wishes while he can take full part, by the three-month review. Outcome by 2026-08-04: Health care agent named and his wishes recorded at the three-month review. **S**

## Medication changes

- Stopped: Donepezil 5 mg oral tablet, one tablet by mouth each morning **S**
- Started: Donepezil 10 mg oral tablet, one tablet by mouth each morning **S**

## Guideline basis

- Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001), American Academy of Neurology (Neurology)
- Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology (2010), American Academy of Neurology (Neurology)
- Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2025), Alzheimer's Association (Alzheimer's & Dementia)
- American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023), American Geriatrics Society
- CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026), Aether Forge

## Follow-up

- Annual wellness visit in about six weeks. Six-month dementia review in about three months. **S**
- Next scheduled visit 2026-09-15: subsequent annual wellness visit. **S**
